RedHill Biopharma Explores Opaganib for Ebola Virus Amid Outbreak

RedHill Biopharma Ltd. has announced its intent to advance its investigational drug, opaganib, to address the current Ebola virus outbreak. The focus lies on the Bundibugyo ebolavirus, a rare subtype without approved treatments. Opaganib has shown promise in Phase 3 trials for severe COVID-19, reducing mortality by 70.2% when paired with standard care. The drug's mechanisms against Ebola involve inhibition of critical cellular pathways for filovirus entry and replication.

RedHill engages in discussions with the World Health Organization and potential pharma collaborations for further clinical trials. Opaganib aims to enhance global infectious disease preparedness with its host-directed therapeutic approach. The drug is noted for its oral administration convenience, ease of storage, and demonstrated safety in prior trials.